A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection.
We have completed a phase 1 safety and immunogenicity trial with hepatitis C virus (HCV) envelope glycoproteins, E1 and E2, with MF59 adjuvant as a candidate vaccine. Neutralizing activity to HCV genotype 1a was detected in approximately 25% of the vaccinee sera. In this study, we evaluated vaccinee...
Main Authors: | Keith Meyer, Arup Banerjee, Sharon E Frey, Robert B Belshe, Ranjit Ray |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3161815?pdf=render |
Similar Items
-
The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein
by: Netanel Tzarum, et al.
Published: (2018-06-01) -
Oncogenic Potential of Hepatitis C Virus Proteins
by: Ranjit Ray, et al.
Published: (2010-09-01) -
A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans.
by: John Lok Man Law, et al.
Published: (2013-01-01) -
Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.
by: Kai Deng, et al.
Published: (2015-01-01) -
Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins.
by: Gerald V Quinnan, et al.
Published: (2013-01-01)